Uniphar (UPR) Share Price, News & Analysis

Company Overview

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

Key Stats

• Today's Range: 320 to 328
• 50-Day Range: 220 to 327.25
• 52-Week Range: 163 to 328
• Volume: 39,492 shs
• Average Volume: 30,272 shs
• Market Capitalization: £1.01 billion
• P/E Ratio: 22.53
• Dividend Yield: 0.62%
• Price Target: GBX 310
• Consensus Rating: Buy

UPR Stock Analysis - Frequently Asked Questions

How have UPR shares performed this year?

Uniphar's stock was trading at GBX 170.80 at the start of the year. Since then, UPR stock has increased by 92.0% and is now trading at GBX 328.
View the best growth stocks for 2025 here.

How do I buy shares of Uniphar?

Shares of UPR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Uniphar own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Uniphar investors own include IXICO (IXI) and ANGLE (AGL).

Company Calendar

• Record date for 5/16 Dividend: 4/24/2025
• Ex-Dividend for 5/16 Dividend: 4/24/2025
• Dividend Payable: 5/16/2025
• Today: 6/17/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Distribution
• Sub-Industry: N/A
• Current Symbol: LON:UPR
• CIK: N/A
• Web: www.uniphar.ie
• Phone: 353 1 428 7777
• Fax: N/A
• Employees: 3,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 310
• High Stock Price Target: GBX 310
• Low Stock Price Target: GBX 310
• Potential Upside/Downside: -5.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 14.38
• Trailing P/E Ratio: 22.76
• Forward P/E Ratio: 17.39
• P/E Growth: N/A
• Net Income: £51.04 million
• Net Margins: 1.68%
• Pretax Margin: N/A
• Return on Equity: 13.18%
• Return on Assets: 3.76%

Debt

• Debt-to-Equity Ratio: 119.48
• Current Ratio: 0.90
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: £3.03 billion
• Price / Sales: 0.34
• Cash Flow: GBX 32.84 per share
• Price / Cash Flow: 9.97
• Book Value: GBX 127.58 per share
• Price / Book: 2.57

Miscellaneous

• Outstanding Shares: 311,281,806
• Free Float: N/A
• Market Cap: £1.02 billion
• Optionable: Not Optionable
• Beta: 0.75